
    
      This study is a phase III, open label safety study with a six month active dosing period. All
      subjects will be started at 12.5 mg Androxal and titrated to 25 mg if needed. Safety will be
      assessed by physical and visual acuity exams, slit lamp eye exams, clinical laboratory tests
      and adverse event reporting.
    
  